News and Trends 25 Nov 2024 Evotec on the brink of acquisition: At what cost for the biotech industry? As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech landscape. November 25, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2023 Evotec receives $6.6M for tuberculosis drug discovery On World Tuberculosis Day, Evotec SE has announced that it has received a $ 6.6 million grant from The Bill & Melinda Gates Foundation for drug discovery to tackle tuberculosis. The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the company to progress a portfolio of TB […] March 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Nov 2022 Breakpoint Therapeutics sabotages DNA repair in cancer cells The Hamburg-based Evotec spinout Breakpoint Therapeutics is working on cancer treatments that block the ability of tumor cells to repair their own DNA. In the last decade, a new class of drugs known as DNA damage response (DDR) inhibitors has risen to prominence in the oncology space. These drugs are able to break down the […] November 2, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Partnership for better understanding of Sjögren’s syndrome announced by Evotec A molecular patient database for Sjögren’s syndrome (SjS) and systemic lupus erythematosus (SLE) is to be generated following a partnership between Evotec SE and a German university. Evotec made the announcement yesterday (Tuesday) that it will work with Hannover Medical School (MHH). The strategic partnership between Evotec and MHH aims at achieving a better understanding […] October 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […] September 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Biologics manufacturing facility launched by Evotec SE in Toulouse Construction of a biologics manufacturing facility commenced on Friday (September 16). It is being built by Evotec at its Campus Curie in Toulouse, is the second facility of its kind, and the first in Europe. It will use Just – Evotec Biologics’ flexible J.POD technology to deliver clinical and commercial manufacturing capacity for biologics. Therapeutic […] September 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Evotec SE acquires highly-flexible drug manufacturing space for €1 A clinical and commercial manufacturing platform for small molecule therapeutics has expanded following an acquisition signed for. Evotec SE made the announcement today (August 25) after signing the contract yesterday for €1 to take Central Glass Germany GmbH from Japanese manufacturing company Central Glass Co. Ltd. It will now operate as Evotec Drug Substance (Germany) […] August 25, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Evotec completes acquisition of Rigenerand An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company. Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed. Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Evotec adds cell therapy manufacturing facility through Rigenerand takeover German headquartered life science company Evotec SE has acquired 100% of the capital of Rigenerand Srl, an Italian cell technology company, for €23M ($24.7M). Founded in 2009 as a spin-off of the University of Modena and Reggio Emilia in Italy, Rigenerand is based in Medolla, Italy, about 100 km south of Evotec’s Campus Levi-Montalcini in […] May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 Evotec, Sernova in partnership to develop beta cell diabetes therapy Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […] May 19, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2021 The Billion-Euro European Biotech Companies in 2022 Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […] December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2021 Evotec IPO Hints At Stabilizing Investor Interest In Biotech Stocks German life sciences heavyweight Evotec raised around €376M ($435M) in its US debut on the Nasdaq last week, fueling tentative hopes of renewed investor interest in biotech stocks after a rollercoaster year. The company downsized its initial IPO target of around €500M ($576M) by offering fewer shares than initially planned. This is widely seen as […] November 10, 2021 - 4 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email